A Heterologous Prime-Boost Vaccination With a Peptide-Based Vaccine & Viral Vector Improves Antitumour Therapy in Preclinical Models. Maximise the Potential of In Vivo Studies to Validate a Platform Preclinically & Prepare for Regulatory Interactions
Time: 2:15 pm
day: Day One
Details:
- Investigating regimen, combination and vaccine MoA supported by preclinical studies
- Harnessing preclinical models to study changes in the tumour microenvironment and T-cell function after vaccination
